A novel immunoassay to measure total serum lymphotoxin-α levels in the presence of an anti-LTα therapeutic antibody.

[1]  P. Hass,et al.  Complement Inhibition in Cynomolgus Monkeys by Anti–Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[2]  John C. Davis,et al.  Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) , 2014, Arthritis Research & Therapy.

[3]  M. Merchant,et al.  Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab , 2013, Molecular Cancer Therapeutics.

[4]  S. Hymowitz,et al.  Dimerization of LTβR by LTα1β2 is necessary and sufficient for signal transduction , 2013, Proceedings of the National Academy of Sciences.

[5]  M. Balázs,et al.  In Vivo Depletion of Lymphotoxin-Alpha Expressing Lymphocytes Inhibits Xenogeneic Graft-versus-Host-Disease , 2012, PloS one.

[6]  Yufang Yang,et al.  The Mechanism of Speech Processing in Congenital Amusia: Evidence from Mandarin Speakers , 2012, PloS one.

[7]  L. Crofford,et al.  Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine , 2012, Arthritis Research & Therapy.

[8]  John C. Davis,et al.  Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial , 2012, Arthritis Research & Therapy.

[9]  Ya-jun Guo,et al.  Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects , 2012, mAbs.

[10]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[11]  M. Washabaugh,et al.  Pharmacokinetic immunoassay methods in the presence of soluble target. , 2010, Journal of immunological methods.

[12]  R. Hansen,et al.  Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets , 2010, mAbs.

[13]  K. Wolslegel,et al.  Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. , 2010, Cytokine.

[14]  Jean W. Lee,et al.  Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. , 2010, Journal of pharmaceutical and biomedical analysis.

[15]  W. Sandoval,et al.  Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration , 2009, mAbs.

[16]  M. Balázs,et al.  Targeted depletion of lymphotoxin-α–expressing TH1 and TH17 cells inhibits autoimmune disease , 2009, Nature Medicine.

[17]  Helen J. Lachmann,et al.  In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes , 2009, The Journal of experimental medicine.

[18]  T. McDonnell,et al.  Comparison of interferon γ release assays and conventional screening tests before tumour necrosis factor α blockade in patients with inflammatory arthritis , 2009, Annals of the rheumatic diseases.

[19]  R. Konrad,et al.  A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker. , 2008, Journal of pharmaceutical and biomedical analysis.

[20]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[21]  F. O'Gara,et al.  High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations , 2008, Rheumatology International.

[22]  F. Aloisi,et al.  Lymphoid neogenesis in chronic inflammatory diseases , 2006, Nature Reviews Immunology.

[23]  J. Aguillón,et al.  Tumour necrosis factor (TNF)α −308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis , 2006 .

[24]  L. Presta,et al.  Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. , 2004, Journal of immunological methods.

[25]  W. O'Fallon,et al.  Lymphoid Neogenesis in Rheumatoid Synovitis1 , 2001, The Journal of Immunology.

[26]  B. Fendly,et al.  Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor β1 , 1995 .

[27]  F. Finkelman,et al.  Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. , 1993, Journal of immunology.

[28]  Carl F. Ware,et al.  Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface , 1993, Cell.

[29]  B. Klein,et al.  High amounts of circulating interleukin (IL)‐6 in the form of monomeric immune complexes during anti‐IL‐6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo , 1992, European journal of immunology.

[30]  A. Rowland,et al.  Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. , 1991, The Journal of clinical endocrinology and metabolism.

[31]  M. Feldmann,et al.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[32]  C. Ware,et al.  Lymphotoxin and an associated 33-kDa glycoprotein are expressed on the surface of an activated human T cell hybridoma. , 1991, Journal of immunology.

[33]  H. P. Fell,et al.  Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal anticarcinoma antibody. , 1990, Cancer research.

[34]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.